Diabetes Discourse

Why are people living with diabetes more likely to die with flu and pneumonia? During flu epidemics, this risk is particularly high when additional risk factors present such as cardiovascular disease and kidney disease. Join guest host Dr. Candis Morello and her guest, pharmacist specializing in ambulatory care, Dr. Sarah Lorentz, as they discuss the reasons immunizations for patients with diabetes are so crucial.

New drug delivery technologies are changing one of the key therapeutic challenges of insulin delivery in the management of diabetes. Join guest host Dr. Candis Morello and her guest, Dr. Brookie Best, assistant clinical professor of pharmacy and pediatrics at University of California San Diego, as they discuss the emerging new technologies being developed in this space.

The new American Association of Clinical Endocrinologists (AACE) guidelines represent a major shift in the way type 2 diabetes is treated. An emphasis on hypoglycemia, adherence to therapy and new medications are included in this new algorithm. Join host Dr. Steven Edelman and his guest, president-elect of AACE, Dr. Daniel Einhorn, as they discuss the principles underlying the new guidelines and how they differ from other guidelines.

Diabetes is the most common cause of kidney failure. However, most people with diabetes can avoid end-stage kidney disease and minimize their risk of kidney failure with intensive management of diabetes. Join host Dr. Steven Edelman and his guest, nephrologist and professor of medicine at the University of California San Diego, Dr. David Ward as they discuss diagnosis, symptoms, prevention and treatment of diabetic kidney disease.

Lowering blood sugar levels in critically ill patients is a widely embraced practice. But according to the results of the NICE-SUGAR study, lowering blood glucose levels in ICU patients may not be safe. Join host Dr. Steven Edelman and his guest, Dr. Irl Hirsch, professor of medicine and the Diabetes Treatment and Teaching chair at the University of Washington in Seattle, as they discuss the results of the NICE-SUGAR study and its implications for treating critically ill patients.

Characterized by high blood sugar levels first recognized during pregnancy, gestational diabetes affects about four percent of all pregnant women. Join host Dr. Steven Edelman and Dr. Thomas Moore, director of perinatal medicine at University of California, San Diego Medical Center, as they discuss the diagnosis and treatment for gestational diabetes.

According to a recent study, people with type 2 diabetes are not meeting important nutritional recommendations. Finding the correct balance of carbohydrates, protein and fat along with portion control and moderation is a challenge. Our guest, dietitian and certified diabetes educator, Lorena Drago, discusses the variance in recommended diets for people living with diabetes. Join host Dr. Steven Edelman to learn more.

SGLT2 is responsible for glucose re-absorption in the kidney and decreasing SGLT2 function promotes glucose excretion to help reduce blood sugar levels, making it an attractive area for the treatment of diabetes. Join host Dr. Steven Edelman and his guest, professor of medicine at Tulane University, Dr. Vivian Fonseca, as they discuss the new class of medications being investigated for the treatment of type-2 diabetes.

Insulin resistance in muscle, liver and ß-cell represent the core pathophysiologic defects in type 2 diabetes. In addition, the ominous octet all play important roles in the development of glucose intolerance in people with type 2 diabetes. How will this new paradigm shift our understanding in the way we treat our type 2 patients? Dr. Ralph DeFronzo, professor of medicine and author of the recent Banting Lecture, “From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus,” discusses new therapies based on the pathophysiology. Join host Dr. Steven Edelman to learn more.

Diabetes therapeutics such as glucose and weight control are major physiological functions of the new glucagon-like peptide-1 (GLP-1) agonists. But is there evidence to suggest that GLP-1 may also have some cardiovascular benefits? Join host Dr. Steven Edelman and Dr. John Buse, professor of medicine at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the emerging cardiovascular actions of incretin hormones.